Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Phase 1

Completed

Conditions: Chemotherapeutic Agent Toxicity
Malignant Ovarian Mixed Epithelial Tumor
Primary Peritoneal Carcinoma
Stage II Ovarian Cancer
Undifferentiated Ovarian Carcinoma
Fallopian Tube Carcinoma
Ovarian Mucinous Cystadenocarcinoma
Stage III Ovarian Cancer
Endometrial Adenocarcinoma
Neurotoxicity Syndrome

Interventions: Drug: Paclitaxel
Drug: Cisplatin

First Posted Date: 2008-12-23

Last Posted Date: 2014-12-31

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 23

Registration Number: NCT00814086

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸
Women and Infants Hospital, Providence, Rhode Island, United States

and more 4 locations

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Neoplasms

Interventions: Drug: RG1507
Drug: RO1507
Drug: erlotinib [Tarceva]
Drug: bevacizumab [Avastin]
Drug: pemetrexel
Drug: carboplatin
Drug: capecitabine [Xeloda]
Drug: sorafenib
Drug: temozolomide
Drug: cetuximab
Drug: paclitaxel
Drug: etoposide
Drug: mFOLFOX6
Drug: trastuzumab [Herceptin]
Drug: docetaxel
Drug: gemcitabine
Drug: irinotecan

First Posted Date: 2008-12-19

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 104

Registration Number: NCT00811993

Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BIBW 2992
Drug: Carboplatin
Drug: BIBW2992
Drug: Paclitaxel
Drug: Bevacizumab

First Posted Date: 2008-12-17

Last Posted Date: 2016-03-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 83

Registration Number: NCT00809133

Locations: 🇬🇧
1200.12.4401 Boehringer Ingelheim Investigational Site, Sutton, United Kingdom
🇬🇧
1200.12.4402 Boehringer Ingelheim Investigational Site, London, United Kingdom

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Phase 3

Conditions: Stage I Uterine Corpus Cancer AJCC v7
Endometrial Clear Cell Adenocarcinoma
Neurotoxicity Syndrome
Stage II Uterine Corpus Cancer AJCC v7
Endometrial Serous Adenocarcinoma
Fatigue
Obesity

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Carboplatin
Radiation: Internal Radiation Therapy
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2008-12-12

Last Posted Date: 2019-03-20

Lead Sponsor: Gynecologic Oncology Group

Target Recruit Count: 601

Registration Number: NCT00807768

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

and more 535 locations

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Advanced Squamous Non-Small Cell Lung Cancer

Interventions: Biological: AMG 479
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2008-12-12

Last Posted Date: 2017-03-29

Lead Sponsor: NantCell, Inc.

Target Recruit Count: 49

Registration Number: NCT00807612

Locations: 🇺🇸
Research Site, Madison, Wisconsin, United States

Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Paclitaxel
Drug: Pemetrexed
Drug: Bevacizumab

First Posted Date: 2008-12-12

Last Posted Date: 2015-12-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 44

Registration Number: NCT00807573

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center@Phelps Memorial Hospital, Sleepy Hollow, New York, United States
🇺🇸
Memorial Sloan-Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 2 locations

Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Metastatic Non-small Cell Lung Cancer

Interventions: Drug: CS7017 tablets
Drug: Carboplatin
Drug: Paclitaxel
Drug: Placebo Tablets

First Posted Date: 2008-12-10

Last Posted Date: 2020-05-13

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 111

Registration Number: NCT00806286

Locations: 🇺🇸
Michiana Hematology-Oncology, South Bend, Indiana, United States
🇺🇸
Southern Illinois Hematology/Oncology, Centralia, Illinois, United States
🇺🇸
Signal Point Clinical Research Center, Middletown, Ohio, United States

and more 24 locations

Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy

Phase 1

Completed

Conditions: Solid Tumor
Breast Cancer

Interventions: Drug: Alvespimycin
Drug: Trastuzumab
Drug: Paclitaxel

First Posted Date: 2008-12-05

Last Posted Date: 2011-06-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 29

Registration Number: NCT00803556

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Phase 3

Completed

Conditions: Stage IVB Cervical Cancer
Cervical Adenosquamous Carcinoma
Cervical Adenocarcinoma
Cervical Squamous Cell Carcinoma
Recurrent Cervical Carcinoma

Interventions: Biological: Bevacizumab
Drug: Cisplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Topotecan Hydrochloride
Other: Questionnaire Administration
Other: Quality-of-Life Assessment

First Posted Date: 2008-12-05

Last Posted Date: 2019-07-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 452

Registration Number: NCT00803062

Locations: 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸
Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 543 locations

A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: bevacizumab [Avastin]
Drug: erlotinib [Tarceva]
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2008-12-02

Last Posted Date: 2014-11-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 91

Registration Number: NCT00800202

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy